Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Relieves osteoarthritis. Sold as Mobic, Meloxicam, Vivlodex, Anjeso, Qmiiz Odt and 2 more. Every FDA application for this active ingredient: 7 branded and 26 generic.
As of Nov 13, 2026, FDA lists 33 applications for Meloxicam (sold as Mobic, Meloxicam, Vivlodex and others), first approved Apr 13, 2000, with 3 new uses approved and 2 published complete response letters.
First approved: Apr 13, 2000
Applications: 33
New uses approved: 3
Complete response letters: 2
Medicare spending, 2025: $74.9M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Boehringer Ingelheim
Cipla
Aurobindo Pharma
Lupin